<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMILORIDE HYDROCHLORIDE</span><br/>(a-mill'oh-ride)<br/><span class="topboxtradename">Midamor<br/></span><b>Classifications:</b> <span class="classification">electrolyte and water balance agents</span>; <span class="classification">diuretics, potassium-sparing</span><br/><b>Prototype: </b>Spironolactone<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potassium-sparing diuretic with mild diuretic and antihypertensive action. Diuretic action is independent of aldosterone and
         carbonic anhydrase.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces urinary excretion of sodium and reduces excretion of potassium and hydrogen ions by direct action on distal renal
         tubules.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Potassium-sparing effect in prevention or treatment of diuretic-induced hypokalemia in patients with CHF, hepatic cirrhosis,
         or hypertension. Also used in management of primary hyperaldosteronism. Usually combined with a potassium-wasting (kaliuretic)
         diuretic such as a thiazide or loop diuretic.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>With hydrochlorothiazide for recurrent calcium nephrolithiasis, lithium-induced polyuria.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Elevated serum potassium (&gt;5.5 mEq/L), concomitant use of other potassium-sparing diuretics; anuria, acute or chronic renal
         insufficiency; evidence of diabetic nephropathy; type 1 diabetes mellitus; metabolic or respiratory acidosis; hepatic function
         impairment. Safety during pregnancy (category B), lactation, or in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Debilitated patients; diet-controlled or uncontrolled diabetes mellitus; cardiopulmonary disease; the older adult.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diuretic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg/d, may increase up to 20 mg/d in 12 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give once/d dose in the morning and schedule the second b.i.d. dose early to avoid interrupting sleep.</li>
<li>Give with food to reduce possibility of gastric distress.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Generally well tolerated. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, nervousness, confusion, paresthesias, drowsiness. <span class="typehead">CV:</span> Cardiac arrhythmias. <span class="typehead">Metabolic:</span> Hyperkalemia, hyponatremia, positive Coombs' test. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Aplastic anemia</span>. <span class="typehead">Special Senses:</span> Tinnitus; nasal congestion. Visual disturbances, increased intraocular pressure. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea</span> or constipation, anorexia, <span class="speceff-common">nausea,</span> vomiting, abdominal cramps, dry mouth, thirst. <span class="typehead">Urogenital:</span> Polyuria, dysuria, bladder spasms, urinary frequency, impotence, decreased libido. <span class="typehead">Respiratory:</span> Dyspnea, shortness of breath. <span class="typehead">Skin:</span> Rash, pruritus, photosensitivity reactions. <span class="typehead">Other:</span> Weakness, fatigue, muscle cramps. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Manufacturer advises discontinuing amiloride in patients with diabetes mellitus at least 3 d before <span class="alt">glucose tolerance</span> test.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Blood from blood banks, <span class="classification">ace inhibitors</span> (e.g., <b>captopril</b>), <b>spironolactone,</b>
<b>triamterene,</b>
<span class="classification">potassium supplements</span> may cause hyperkalemia with cardiac arrhythmias; possibility of increased <b>lithium</b> toxicity (decreased renal elimination); possibility of altered <b>digoxin</b> response; <span class="classification">nsaid</span>s may attenuate antihypertensive effects. <span class="typehead">Food:</span>
<span class="classification">potassium-containing salt substitutes</span> increase risk of hyperkalemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 50% absorbed from GI tract. <span class="typehead">Onset:</span>  2 h. <span class="typehead"> Peak:</span>  610 h. <span class="typehead"> Duration:</span> 24 h. <span class="typehead">Elimination:</span> 2050% excreted unchanged in urine, 40% in feces. <span class="typehead">Half-Life:</span> 69 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hyperkalemia and hyponatremia (see Appendix F). Hyperkalemia occurs in about 10% of patients receiving
            amiloride and serum potassium can rise suddenly and without warning. It is more common in older adults and patients with diabetes
            or renal disease.
         </li>
<li>Lab tests: Serum potassium levels, particularly when therapy is initiated, whenever dosage adjustments are made, and during
            any illness that may affect kidney function. Intermittent evaluations of BUN, creatinine, and ECG for patients with renal
            or hepatic dysfunction, diabetes mellitus, older adults, or the debilitated.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn S&amp;S of hyperkalemia and hyponatremia (see Appendix F) and report to physician immediately.</li>
<li>Do not take potassium supplements, salt substitutes, high intake of dietary potassium unless prescribed by physician.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>